SEO URLwww.firestrike.ai/deals/neurocrine-group-limited-immedica-acquisition-2026

acquisitionAnnounced · Jan 8, 2026PharmaceuticalsSource · CredibleArticle · Factual

Neurocrine Group Limited · Immedica

Immedica acquires Neurocrine Group Limited

David Najork · Founding Software Engineer

Published Apr 29, 2026 · Updated Apr 29, 2026 · 1 min read

ShareX LinkedIn Email

Deal value

$65M

Target

Neurocrine Group Limited

Acquirer

Immedica

Full Acquisition

Status

Pending

Immedica agreed to acquire Neurocrine Group Limited. Reported deal value: $65M. Status: Pending. Sector: Pharmaceuticals. Target headquarters context: Location not specified.

This page summarizes publicly available information about the transaction as of 2026-01-08. Figures and status may change as filings and press coverage update.

Immedica to acquire Neurocrine Group Limited , Neurocrine Biosciences ’ European rare commercial business Thu, Jan 08, 2026 18:00 CET Report this content Portfolio includes global rights to Alkindi® and global rights ex-US to Efmody® Stockholm , Sweden – January 8, 2026 - Immedica Pharma AB today announced that it has entered into a definitive agreement to acquire Neurocrine Group Limited and subsidiaries , including the assets and global rights to Alkindi® ( hydrocortisone oral granules and the assets and global rights to Efmody® , from Neurocrine Biosciences

Deal timeline

Announced

Jan 8, 2026 · news.cision.com

Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.

Sector context

This transaction is classified in Pharmaceuticals with a reported deal value of $65M. Figures and status may change as sources update.

Sources: news.cision.com · Primary article · FireStrike proprietary index